by CN Bio. | May 5, 2021 | Press releases
The FDA expands collaboration with CN Bio to investigate lung-on-a-chip model for inhaled drug evaluation applications Extension aims to evaluate CN Bio’s PhysioMimix lung-on-a-chip platform in addition to deepening existing research collaboration for liver studies...
by CN Bio. | Apr 21, 2021 | NASH
Liver disease is a serious worldwide problem linked to approximately two million deaths per year and in many cases is entirely preventable (Sumeet et al, 2019). One of the most common causes of chronic liver disease is non-alcoholic fatty liver disease (NAFLD), which...
by CN Bio. | Mar 17, 2021 | Press releases
CN Bio, a leading developer of single and multi-organ microphysiological systems (MPS), otherwise known as organ-on-a-chip (OOC), today announced the commercial launch of its new PhysioMimix™ OOC Multi-Organ MPS. The next-generation platform combines CN Bio’s in vitro...
by CN Bio. | Mar 1, 2021 | Press releases
Funding will advance 3D lung cell culture models to accelerate drug discovery CN Bio, a leading developer of single and multi-organ microphysiological systems (MPS), otherwise known as organ-on-a-chip, today announced it has received a grant from Innovate UK, the UK’s...
by CN Bio. | Feb 17, 2021 | OOC Blog
How Mimicking Blood Flow Makes Organ-on-a-Chip Technology Even More Life-like With every beat of your heart, blood rushes through your body. Some floods your arteries traveling from the lungs back to the heart. Some squeezes almost single-file, one frisbee-shaped...
